bispecific T-cell engager
T-cell responses against CD19 pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
... on T-cell therapy, e.g. ex vivo genetic modification of T cells to express chimeric antigen receptors (CARs) targeting leukemic antigens or by antibody-mediated activation of patients’ T cells ...
18
Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
... The bispecific T cell engager blinatumomab has shown encouraging clinical activity in B-precursor acute lymphoblastic leukemia ...revealed T cell infiltrates and an increase in ...
5
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
... CD3-positive T cells, bypassing T cell receptor (TCR) specificity and major histocompatibility complex (MHC) class I molecules [41, 54, ...induce T-cell- mediated depletion of primary ...
7
Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager
... CARs T-cells has been reported [4, 5, ...FAP5-CAR-transduced T cells led to cachexia and lethal bone toxicities due to FAP expression by multipotent bone marrow stem cells (BMSCs) ...of T cells when ...
15
Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs
... bispecific T cell-engaging (BiTE) antibody tech- nology has demonstrated long-term relapse-free outcomes in patients with relapsed and refractory acute lymphocytic ...of T cells for redirected lysis ...
13
DLL3: an emerging target in small cell lung cancer
... Small cell lung cancer (SCLC) accounts for approximately 15% of all lung ...the bispecific T cell engager immuno-oncology therapy AMG 757, and the chimeric antigen receptor T ...
8
DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity
... has limitations, including slow development timelines, limited modification options, and short half-life for the molecules, requiring frequent repeat administrations. These limitations contribute to the high cost of ...
9
Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene engineered T cells
... of T-cell involvement. In order to enlist and mobilize of T-cells against cancer and maximize antibody targeted therapy, innovative methods have been designed to allow T-cells to be redirected ...
12
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
... activates T cell function through binding of CD3 and is a bispecific antibody construct that is a CD19-directed CD3 T-cell engager (BiTE®) ...
8
Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
... ALL, T-cell-based therapeutic approaches have recently emerged to the forefront in R/R ALL ...Bi-specific T-cell engager (BiTE) antibodies are sophisticated antibod- ies designed to ...
9
A Bispecific Antibody That Simultaneously Recognizes the V2 and V3 Glycan Epitopes of the HIV 1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies
... It has previously been reported that one V2-glycan antibody, PG9, can interfere with neutralization by V3-glycan antibodies in some circumstances (29). Similar interference may account for the inability of PGT145 to ...
16
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
... First, CD14 + CD11b + CD33 + monocytic cells express- ing low levels of HLA-DR (HLA-DR lo ) and resem- bling one of the most established human MDSC-like phenotype [11] as previously described by us in chronic lymphocytic ...
6
Ipilimumab augments antitumor activity of bispecific antibody armed T cells
... that T cells expanded from the leukapheresis product or PBMC from the immuno- suppressive environment of cancer patients can be stim- ulated to improve their functions in vitro as well as in vivo ...cytotoxic ...
11
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
... stimulate T and NK cell reactivity against the primary AML cells as ...and T cells, respectively, contained in PBMC of healthy donors ...+ T cells ...in T cells ...leukemia cell ...
15
Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth
... Serially diluted recombinant human CD44 protein (0-500 nM) was loaded into 96-well microtiter plates at 50μg/well in triplicates and incubated overnight at 4°C. Plates were further blocked with 5% BSA/ sperm DNA (500 ...
16
CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter
... the cell surface expression of the CXCR4 receptor on the panel of cancer cells, we generated a recombinant bispecific adapter molecule, sCAR-CXCL12, by combining ectodomain of hCAR with CXCL12, the ...
15
Immunotherapy in hematologic malignancies: past, present, and future
... CAR T cells would not be complete without highlighting the CRS, an inflammatory process related to exponential T cell proliferation associ- ated with massive cytokine ...CAR T cells have ...
10
Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
... leukemia cell line C1498 was upregulated in vivo, and blocking PD-L1/PD-1 path- way resulted in decreased AML burden and longer sur- vival time ...cytotoxic T cell lysis [27]. In BM aspirates from ...
20
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
... chain bispecific format also targeting a melanoma associated proteogly- can recombinant, in addition to targeting CD28, a co-stimulatory molecule on T cells, showed tumor cell killing without the ...
15
CAR-T cell therapy: a potential new strategy against prostate cancer
... B cell lymphoma ...B cell lymphoma (DLBCL), also sparking off research into solid ...CAR-T cell therapy in hematological ...of cell- directed ...
11